Nestlé Health Science subsidiary ProciseDx has received the European CE Mark for Procise IFX and Procise ADL, the company's infliximab and adalimumab point-of-care diagnostics.
Procise IFX and Procise ADL provide diagnostic data for therapeutic drug monitoring within five minutes of a finger-prick blood sample, the company noted. Both tests run on the ProciseDx system, which is about the size of a shoe box.